Early Access to Avapritinib for Patients with Inoperable or Metastatic Gastrointestinal Stromal Tumor (GIST)


Full Title

Early Access Program (EAP) for Avapritinib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)


This study is an Early Access Program that makes the drug avapritinib available to people with inoperable or metastatic gastrointestinal stromal tumor (GIST). Researchers are continuing to study the safety of the drug and see whether it causes few or mild side effects.

Avapritinib interferes with proteins that may promote the growth of some kinds of digestive cancer cells. The researchers think that blocking those proteins may cause GIST cells to die. Avapritinb is taken orally (by mouth).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have inoperable or metastatic GIST and not be eligible for other ongoing clinical trials of avapritinib.
  • Patients’ cancers must continue to grow despite at least three prior regimens of TKI inhibitor drugs, including imatinib, or must have a mutation in exon 18 of the PDGFRA gene.
  • This study is for patients age 16 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Mary Keohan at 646-888-4160.



Disease Status

Newly Diagnosed & Relapsed/Refractory